Adaptyx Biosciences, a biowearables company developing the first platform for continuous, multi-analyte molecular monitoring, today announced it has raised $14 million in seed financing, bringing total funding to $23 million since inception. The round was led by Interlagos, with significant participation from Overwater Ventures, and joined by Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Ventures..

Adaptyx Biosciences是一家开发生物可穿戴设备的公司，正在开发首个用于持续多分析物分子监测的平台，今天宣布已完成1400万美元的种子轮融资，使其自成立以来的总融资额达到2300万美元。本轮融资由Interlagos领投，Overwater Ventures显著参与，Starbloom Capital、斯坦福大学、陈-扎克伯格生物中心、Hyperlink Ventures、Cantos Ventures、Humba Ventures和Seaside Ventures共同参投。

Adaptyx's biowearable platform redefines continuous health monitoring, moving beyond glucose to capture a much wider range of human biochemistry - including small molecules, electrolytes, hormones, drugs, and proteins - making visible what has long been hidden between lab visits. By pairing continuous molecular sensing with AI-powered analytics, the platform transforms these data streams into actionable insights, enabling earlier detection of health trends and timely interventions before issues escalate..

Adaptyx的生物可穿戴平台重新定义了持续健康监测，不仅限于葡萄糖，还能捕捉更广泛的人体生化指标——包括小分子、电解质、激素、药物和蛋白质——揭示长期以来在实验室访问之间隐藏的信息。通过将连续的分子传感与人工智能驱动的分析相结合，该平台将这些数据流转化为可操作的洞察，从而实现对健康趋势的早期检测，并在问题恶化之前进行及时干预。